CD8A and neoplasm: For instance, systemic injection of anti-Thy1 liposomal TGF-β inhibitor after pmel-1 Thy1.1+ CD8+ T cell therapy in a B16F10 tumor model showed better tumor regression and total survival rates compared to ACT T cells with and without free drug [201].